Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC) Animal Free,Azide Free,Carrier Free,ExactAb™,Low Endotoxin,Recombinant,Validated for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C,Avoid repeated freezing and thawing Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Netakimab (anti-IL-17A) is an anti-IL-17 monoclonal antibody. Netakimab (anti-IL-17A) can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis.
Netakimab (anti-IL-17A) (Ab191931) - ELISA
Immobilized Recombinant Human CTLA-8 / IL-17a protein at 2.0 μg/mL can bind Netakimab (anti-IL-17A) (Ab191931) with the EC50 of 14.02 ng/mL.
Netakimab (anti-IL-17A) (Ab191931) - SEC
The purity of Netakimab (anti-IL-17A) (Ab191931) is more than 95% verified by HPLC.
Netakimab (anti-IL-17A) (Ab191931) - ELISA
Immobilized Recombinant Human IL-17A protein (rp169639) at 2.0 μg/mL can bind Netakimab (anti-IL-17A) (Ab191931) with the EC₅₀ of 21.7 ng/mL.
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Animal Free grade guide → View Carrier Free grade guide → View Recombinant grade guide → View Validated grade guide → View ExactAb™ grade guide → View Low Endotoxin grade guide → View Azide Free grade guide →
